Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ventana snaps up Spring Bioscience

This article was originally published in The Gray Sheet

Executive Summary

Tissue-based cancer diagnostics firm Ventana gains next generation rabbit monoclonal antibodies and other reagents to aid development of companion diagnostics for use with drugs through its $28.9 million cash purchase of Spring Bioscience. Announced Sept. 5, the deal for Fremont, Calif.-based Spring Bioscience will include up to an additional $11.7 million in milestone payments over the next two years - which could put its total value at $40.6 million. As a result of the purchase, Ventana increased its 2008 revenue forecast by $7 million - to a range of $377 million-$392 million. Ventana itself remains subject to a hostile takeover attempt by Roche that values the company at $3 billion (1"The Gray Sheet" Aug. 27, 2007, In Brief)...

You may also be interested in...



Roche’s Ventana bid advances in court

Ventana Medical Systems is preliminarily enjoined from using certain anti-takeover provisions to avert Roche's $3 billion hostile bid for the Tucson-based cancer diagnostics firm under an Arizona federal district court decision Aug. 21. Swiss firm Roche launched its $75-per-share tender offer for Ventana June 27, and has extended the offer's expiration date from Aug. 23 to Sept. 20. The offer represents a 44% premium over Ventana's last stock closing price before the bid was announced, although the market price has since soared as high as $88. Ventana says it remains "steadfast" in its belief that Roche's bid is "wholly inadequate" (1"The Gray Sheet" July 2, 2007, p. 10)...

Real World Data Failed To Impress Kaftrio’s European Reviewers

The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.

Swissmedic Clears Up Confusion Over Validity Of GMP Certificates

Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.

UsernamePublicRestriction

Register

LL018264

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel